PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 158 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2018. The put-call ratio across all filers is 0.47 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $22,000 | +10.0% | 4,729 | 0.0% | 0.01% | -12.5% |
| Q4 2018 | $20,000 | -23.1% | 4,729 | +10.5% | 0.01% | -27.3% |
| Q3 2018 | $26,000 | -25.7% | 4,279 | -1.2% | 0.01% | -26.7% |
| Q2 2018 | $35,000 | +12.9% | 4,329 | 0.0% | 0.02% | +15.4% |
| Q1 2018 | $31,000 | +72.2% | 4,329 | +50.4% | 0.01% | +62.5% |
| Q4 2017 | $18,000 | -14.3% | 2,878 | +0.9% | 0.01% | -20.0% |
| Q3 2017 | $21,000 | +250.0% | 2,852 | +226.7% | 0.01% | +233.3% |
| Q2 2017 | $6,000 | -25.0% | 873 | -0.3% | 0.00% | -25.0% |
| Q1 2017 | $8,000 | 0.0% | 876 | -4.6% | 0.00% | 0.0% |
| Q4 2016 | $8,000 | – | 918 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 8,951,169 | $54,871,000 | 3.38% |
| Virtus ETF Advisers LLC | 103,807 | $636,000 | 1.75% |
| BKS ADVISORS, LLC | 291,150 | $1,785,000 | 0.92% |
| Piermont Capital Management Inc. | 363,549 | $2,229,000 | 0.71% |
| TUDOR INVESTMENT CORP ET AL | 2,370,760 | $14,532,000 | 0.41% |
| SEARLE & CO. | 60,000 | $349,000 | 0.34% |
| TURNER INVESTMENTS LLC | 252,785 | $1,550,000 | 0.32% |
| RICE HALL JAMES & ASSOCIATES, LLC | 891,672 | $5,466,000 | 0.31% |
| Phocas Financial Corp. | 635,333 | $3,895,000 | 0.30% |
| TFS CAPITAL LLC | 398,283 | $2,441,000 | 0.26% |